Recent is een studie verschenen in het JOURNAL OF DERMATOLOGICAL TREATMENT, genaamd:
Association of lymphopenia and eosinophilia with dimethylfumarate treatment efficacy and tolerability in psoriasis: a retrospective study
De studie is uitgevoerd door twee artsen van het Maxima Medisch Centrum
D.F.C van Hezik and H. J. Bovenschen
Department of Dermatology, Maxima Medical Center Veldhoven, Veldhoven, The Netherlands
Met andere woorden als ik dit goed interpreteer staat er zoveel als: Als je lymfocyten omlaag gaan is dat een teken dat de DMF goed werkt en als je eosinofielen omhoog gaan, dan is er grotere kans dat je bijwerkingen hebt.
Background: Dimethylfumarate (DMF) is an effective treatment for psoriasis, which may cause side effects in a considerable group of patients. Alterations in white blood cell (WBC) counts may predict treat- ment success and the occurrence of side effects.
Objectives: To analyze WBC counts with respect to efficacy and the prevalence of side effects during DMF therapy for psoriasis.
Methods and materials: Psoriasis patients were treated with DMF. Retrospective data (WBC counts, treat- ment results, and side effects) were analyzed to assess correlations with respect to efficacy, tolerability, and leukocyte subsets.
Results: Of 95 patients treated with DMF, 60 patients (63.2%) had treatment success at week 16 and 77 patients (81.1%) experienced side effects. Absolute lymphocyte counts were more decreased in the treat- ment success group versus the treatment failure group: 1.1 (±0.7 SD) versus 0.6 (±0.6 SD); p<.05. Eosinophil counts were more increased in the group with side effects versus the group without side effects: 3.8 (±5.5 SD) versus 1.2 (±2.5 SD); p<.05. However, direct correlation studies showed no statistic- ally significant correlations.
Conclusions: Lymphopenia is associated with better clinical results of DMF treatment for psoriasis, whereas eosinophilia is associated with the occurrence of side effects.